Johnson & Johnson (JNJ)

$160.64

+1

(+0.63%)▲

Market is closed - opens 7 PM, 29 Jul 2024
star icon

Johnson & Johnson is a healthcare company that produces and sells a variety of products, including medical devices, pharmaceuticals, and consumer healthcare goods.

Performance

  • $159.74
    $161.54
    $160.64
    downward going graph

    0.56%

    Downside

    Day's Volatility :1.11%

    Upside

    0.56%

    downward going graph
  • $141.57
    $170.63
    $160.64
    downward going graph

    11.87%

    Downside

    52 Weeks Volatility :17.03%

    Upside

    5.85%

    downward going graph

Returns

PeriodJohnson & JohnsonSector (Health Care)Index (NASDAQ Composite)
3 Months
9.24%
6.5%
4.4%
6 Months
0.09%
7.1%
4.8%
1 Year
-7.57%
9.8%
12.4%
3 Years
-7.12%
14.2%
13.6%

Highlights

Market Capitalization
376.1B
Book Value
$29.09
Dividend Share
4.81
Dividend Yield
3.17%
Earnings Per Share (EPS)
6.53
PE Ratio
23.93
PEG Ratio
0.89
Wall Street Target Price
171.47
Profit Margin
43.91%
Operating Margin TTM
29.43%
Return On Assets TTM
8.01%
Return On Equity TTM
24.24%
Revenue TTM
86.6B
Revenue Per Share TTM
35.59
Quarterly Revenue Growth YOY
2.3%
Gross Profit TTM
64.0B
EBITDA
31.1B
Diluted Eps TTM
6.53
Quarterly Earnings Growth YOY
0.11
EPS Estimate Current Year
10.01
EPS Estimate Next Year
10.71
EPS Estimate Current Quarter
2.64
EPS Estimate Next Quarter
2.73

Analyst Recommendation

Buy
    53%Buy
    46%Hold
    0
    0%Sell
Based on 28 Wall street analysts offering stock ratings for Johnson & Johnson(by analysts ranked 0 to 5 stars)
Based on 28 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
13
14
Hold
13
14
13
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 6.74%

Current $160.64
Target $171.47

Company Financials

FY18Y/Y Change
Revenue
81.6B
↑ 6.71%
Net Income
15.3B
↑ 1076.69%
Net Profit Margin
18.75%
↑ 17.05%
FY19Y/Y Change
Revenue
82.1B
↑ 0.59%
Net Income
15.1B
↓ 1.16%
Net Profit Margin
18.42%
↓ 0.33%
FY20Y/Y Change
Revenue
82.6B
↑ 0.64%
Net Income
14.7B
↓ 2.68%
Net Profit Margin
17.82%
↓ 0.6%
FY21Y/Y Change
Revenue
93.8B
↑ 13.55%
Net Income
20.9B
↑ 41.89%
Net Profit Margin
22.26%
↑ 4.44%
FY22Y/Y Change
Revenue
94.9B
↑ 1.25%
Net Income
17.9B
↓ 14.07%
Net Profit Margin
18.9%
↓ 3.36%
FY23Y/Y Change
Revenue
85.2B
↓ 10.31%
Net Income
35.2B
↑ 95.94%
Net Profit Margin
41.28%
↑ 22.38%
Q4 FY22Q/Q Change
Revenue
23.7B
↓ 0.36%
Net Income
3.5B
↓ 21.04%
Net Profit Margin
14.85%
↓ 3.89%
Q1 FY23Q/Q Change
Revenue
24.7B
↑ 4.34%
Net Income
-68.0M
↓ 101.93%
Net Profit Margin
-0.27%
↓ 15.12%
Q2 FY23Q/Q Change
Revenue
25.5B
↑ 3.28%
Net Income
5.1B
↓ 7664.71%
Net Profit Margin
20.14%
↑ 20.41%
Q3 FY23Q/Q Change
Revenue
21.3B
↓ 16.44%
Net Income
26.0B
↑ 405.99%
Net Profit Margin
121.94%
↑ 101.8%
Q4 FY23Q/Q Change
Revenue
21.4B
↑ 0.22%
Net Income
4.0B
↓ 84.44%
Net Profit Margin
18.93%
↓ 103.01%
Q1 FY24Q/Q Change
Revenue
21.4B
↓ 0.04%
Net Income
3.3B
↓ 19.61%
Net Profit Margin
15.22%
↓ 3.71%
FY18Y/Y Change
Total Assets
153.0B
↓ 2.76%
Total Liabilities
93.2B
↓ 4.06%
FY19Y/Y Change
Total Assets
157.7B
↑ 3.12%
Total Liabilities
98.3B
↑ 5.42%
FY20Y/Y Change
Total Assets
174.9B
↑ 10.88%
Total Liabilities
111.6B
↑ 13.6%
FY21Y/Y Change
Total Assets
182.0B
↑ 4.07%
Total Liabilities
108.0B
↓ 3.24%
FY22Y/Y Change
Total Assets
187.4B
↑ 2.94%
Total Liabilities
110.6B
↑ 2.39%
FY23Y/Y Change
Total Assets
167.6B
↓ 10.58%
Total Liabilities
98.8B
↓ 10.66%
Q4 FY22Q/Q Change
Total Assets
187.4B
↑ 7.0%
Total Liabilities
110.6B
↑ 10.0%
Q1 FY23Q/Q Change
Total Assets
196.0B
↑ 4.58%
Total Liabilities
125.1B
↑ 13.14%
Q2 FY23Q/Q Change
Total Assets
191.7B
↓ 2.19%
Total Liabilities
115.3B
↓ 7.85%
Q3 FY23Q/Q Change
Total Assets
166.1B
↓ 13.37%
Total Liabilities
94.8B
↓ 17.73%
Q4 FY23Q/Q Change
Total Assets
167.6B
↑ 0.9%
Total Liabilities
98.8B
↑ 4.17%
Q1 FY24Q/Q Change
Total Assets
172.0B
↑ 2.63%
Total Liabilities
101.9B
↑ 3.2%
FY18Y/Y Change
Operating Cash Flow
22.2B
↑ 5.44%
Investing Cash Flow
-3.2B
↓ 78.7%
Financing Cash Flow
-18.5B
↑ 141.24%
FY19Y/Y Change
Operating Cash Flow
23.4B
↑ 5.47%
Investing Cash Flow
-6.2B
↑ 95.58%
Financing Cash Flow
-18.0B
↓ 2.67%
FY20Y/Y Change
Operating Cash Flow
23.5B
↑ 0.51%
Investing Cash Flow
-20.8B
↑ 236.21%
Financing Cash Flow
-6.1B
↓ 66.03%
FY21Y/Y Change
Operating Cash Flow
23.4B
↓ 0.54%
Investing Cash Flow
-8.7B
↓ 58.3%
Financing Cash Flow
-14.0B
↑ 129.53%
FY22Y/Y Change
Operating Cash Flow
21.2B
↓ 9.47%
Investing Cash Flow
-12.4B
↑ 42.47%
Financing Cash Flow
-8.9B
↓ 36.85%
FY23Y/Y Change
Operating Cash Flow
22.8B
↑ 7.54%
Investing Cash Flow
878.0M
↓ 107.1%
Financing Cash Flow
-15.8B
↑ 78.39%
Q4 FY22Q/Q Change
Operating Cash Flow
5.4B
↓ 14.86%
Investing Cash Flow
-4.4B
↑ 158.5%
Financing Cash Flow
1.7B
↓ 143.31%
Q1 FY23Q/Q Change
Operating Cash Flow
3.3B
↓ 39.12%
Investing Cash Flow
3.3B
↓ 175.39%
Financing Cash Flow
6.1B
↑ 261.06%
Q2 FY23Q/Q Change
Operating Cash Flow
4.2B
↑ 28.4%
Investing Cash Flow
-3.8B
↓ 213.91%
Financing Cash Flow
-6.0B
↓ 197.61%
Q3 FY23Q/Q Change
Operating Cash Flow
7.5B
↑ 79.08%
Investing Cash Flow
2.5B
↓ 167.29%
Financing Cash Flow
-11.3B
↑ 88.9%
Q4 FY23Q/Q Change
Operating Cash Flow
7.9B
↑ 4.99%
Investing Cash Flow
-1.2B
↓ 147.3%
Financing Cash Flow
-4.7B
↓ 58.87%
Q1 FY24Q/Q Change
Operating Cash Flow
3.7B
↓ 53.49%
Investing Cash Flow
-464.0M
↓ 61.4%
Financing Cash Flow
546.0M
↓ 111.73%

Technicals Summary

Sell

Neutral

Buy

Johnson & Johnson is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Johnson & Johnson
Johnson & Johnson
8.73%
0.09%
-7.57%
-7.12%
22.11%
Procter & Gamble Company, The
Procter & Gamble Company, The
-0.33%
6.89%
8.42%
18.98%
45.47%
Pfizer Inc.
Pfizer Inc.
10.07%
9.87%
-18.89%
-27.82%
-29.96%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Johnson & Johnson
Johnson & Johnson
23.93
23.93
0.89
10.01
0.24
0.08
0.03
29.09
Procter & Gamble Company, The
Procter & Gamble Company, The
27.45
27.45
3.28
6.55
0.32
0.11
0.02
20.87
Pfizer Inc.
Pfizer Inc.
71.0
NA
0.26
2.19
0.0
0.01
0.06
16.28
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Johnson & Johnson
Johnson & Johnson
Buy
$376.1B
22.11%
23.93
43.91%
Procter & Gamble Company, The
Procter & Gamble Company, The
Buy
$396.5B
45.47%
27.45
17.99%
Pfizer Inc.
Pfizer Inc.
Hold
$169.9B
-29.96%
71.0
-0.56%

Insights on Johnson & Johnson

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 21.39B → 21.38B (in $), with an average decrease of 0.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 26.02B → 3.25B (in $), with an average decrease of 52.0% per quarter

  • Vs PG

    In the last 1 year, Procter & Gamble Company, The has given 8.4% return, outperforming this stock by 16.0%

  • Vs PG

    In the last 3 years, Procter & Gamble Company, The has given 19.0% return, outperforming this stock by 26.1%

Institutional Holdings

  • Vanguard Group Inc

    9.51%

  • BlackRock Inc

    7.88%

  • State Street Corporation

    5.55%

  • Geode Capital Management, LLC

    2.22%

  • Morgan Stanley - Brokerage Accounts

    1.77%

  • State Farm Mutual Automobile Ins Co

    1.32%

Corporate Announcements

  • Johnson & Johnson Dividends March,2024

    In the quarter ending March,2024. Johnson & Johnson has declared dividend of $1.19

    Read More

Company Information

Johnson & Johnson - a multinational corporation founded in America - mainly caters to medical and consumer goods. The company's headquarters are in New Jersey, United States. The company was incorporated in 1886 by James, Robert, and Edward Mead Johnson. Johnson & Johnson is one of the world's most valuable corporations. It has nearly 250 subsidiary companies operating across 60 countries. Its products are selling in over 175 countries. Some well-known consumer products of Johnson & Johnson are Band-Aids, baby products, Tylenol medications, and other products. In 2020, Johnson & Johnson generated annual revenue of $82.584 billion. Joaquin Duato serves as the Chairman and CEO for Johnson & Johnson, along with Paul Stoffels as Vice Chairman of the Executive Committee for the company with several other members. The company was ranked 36 on the Fortune 500 list of the top corporations in the United States by total revenue in 2021. Johnson & Johnson is publicly traded on New York Stock Exchange as JNJ as its stock symbol, under the DJIA, S&P 100, and S&P 500. Currently Johnson & Johnson has a market cap of $376.12 Billion. It has a P.E ratio of 9.78. The shares of Johnson & Johnson are trading at $159.64. .

Organization
Johnson & Johnson
Employees
131900
CEO
Mr. Joaquin Duato
Industry
Health Technology

Discover More

FAQs